Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania (PMAL03)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00513669|
Recruitment Status : Completed
First Posted : August 9, 2007
Last Update Posted : March 15, 2013
|Condition or disease||Intervention/treatment||Phase|
|Falciparum Malaria||Biological: PEV 301& 302 in virosomes Biological: Inflexal V (active comparator)||Phase 1|
Volunteers will be screened, enrolled, injected with the vaccine or comparator and followed by the clinicians at the Bagamoyo Research and Training Unit of the the Ifakara Health Research and Development Center (BRTU-IHRDC).
First, 10 adult males will be enrolled and randomized in 2 groups: Group AV (n=8) will be injected with the vaccine combination and group AP (n=2) will be vaccinated with the placebo=comparator (Inflexal V). 5 weeks later, 8 children will be enrolled first and randomized in 2 groups: Group CV (n=6) will be injected with the vaccine combination and group CP (n=2) will be vaccinated with comparator. 1 week later, the rest of the cohort (n=32) will be enrolled and randomized in 2 groups: Group CV (n=26) will be injected with the vaccine combination and group CP (n=6) will be vaccinated with comparator.
Immunogenicity assessments for humoral immune response will be made at baseline (days -10 to -2), day 30 (+4), day 90 (+4) (day of 2nd vaccination), 120 (+4), 180 (+7), and 365 (+14).
Cellular immune responses will be assessed before 1st vaccination (day 0), two weeks after 2nd vaccination (day 104 ±2), and one year after the 1st vaccination (day 365) Safety assessments will be made by the investigator at baseline (days -10 to -2, before the 1st immunization) and at day 1, 2, 3, 7, 14, 30 after each vaccination.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase Ib Double-blind Randomized Placebo Controlled Age-deescalating Trial of Two Virosome Formulated Anti-malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-immune Tanzanian Volunteers|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||March 2009|
Experimental: 1 PEV301&302
The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes
Biological: PEV 301& 302 in virosomes
PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
Active Comparator: 2 Influenza vaccine
Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes
Biological: Inflexal V (active comparator)
Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
- Safety (incidence of local and systemic adverse events) Humoral immunity [ Time Frame: 30 days post-injection ]
- Cell-mediated immunity [ Time Frame: 14 days post-injection ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00513669
|Bagamoyo Research and Training Unit|
|Principal Investigator:||Blaise Genton, MD PhD||Swiss tropical institute, Ifakara Health Research and Development Center|